ChromaDex and the NIH-NIAID Rocky Mountain Laboratories Announce Study to Assess the Therapeutic Potential of Niagen® in COVID-19 Animal Models

LOS ANGELES–(BUSINESS WIRE)—- $CDXC #CellularHealth–ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a preclinical study in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). This study will assess if administration of Niagen® (nicotinamide riboside, or NR) can reduce viral burden and inflammation in mouse and hamster models of COVID-19. ChromaDex’s patent-protected NR is a unique nutrient that supports cellular

ChromaDex and the NIH-NIAID Rocky Mountain Laboratories Announce Study to Assess the Therapeutic Potential of Niagen® in COVID-19 Animal Models

LOS ANGELES–(BUSINESS WIRE)—- $CDXC #CellularHealth–ChromaDex Corp. (NASDAQ:CDXC) announced today the initiation of a preclinical study in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH). This study will assess if administration of Niagen® (nicotinamide riboside, or NR) can reduce viral burden and inflammation in mouse and hamster models of COVID-19. ChromaDex’s patent-protected NR is a unique nutrient that supports cellular